Foresite Capital — 2026 Investments
3 investments dated 2026 · listed companies and verified rows first · show all
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSanofi VenturesMass General Brigham Ventures+8 more
Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.
BiotechDeep TechHealthtechLongevity
Nils Regge(Co-Founder & General Partner)in
Co-investorsBLN CapitalCoastCapFJ LabsKfW CapitalTruVenturo GmbHCTI Life Sciences Fund L.P.+3 more
Slate Medicines is a clinical-stage biotechnology company.
BiotechMedical DevicesBoston, US
Sara Pacheco(Executive Officer)Neil Buckley(Executive Officer, Director)Gregory Frank Oakes(Executive Officer)Gregory Oakes(Chief Executive Officer and Board Director)
BoardTim Lohoff(Director)Cindy Xiong(Director)
Co-investorsRA Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.